Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 952

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 952
---
-1-59</div>

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the day and year first above written.

| Parent:                          |     |                                |
| DENALI CAPITAL ACQUISITION CORP. |     |                                |
| By:                              |     | /s/ Lei Huang                  |
|                                  |     | Name: Lei Huang                |
|                                  |     | Title: Chief Executive Officer |
| Merger Sub:                      |     |                                |
| DENALI MERGER SUB INC.           |     |                                |
| By:                              |     | /s/ Peter Xu                   |
|                                  |     | Name: Peter Xu                 |
|                                  |     | Title: President               |

[Signature Page to the Agreement and Plan of Merger] A-1-60

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the day and year first above written.

| Company:                     |     |                                |
| SEMNUR PHARMACEUTICALS, INC. |     |                                |
| By:                          |     | /s/ Jaisim Shah                |
|                              |     | Name: Jaisim Shah              |
|                              |     | Title: Chief Executive Officer |

[Signature Page to the Agreement and Plan of Merger] A-1-61

**Annex A-2**

<div align='center'>**AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER**</div>

THIS AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of April 16, 2025, is made and entered into by and among Denali Capital Acquisition Corp., a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, “Parent”), Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (the “Merger Sub” and together with Parent, collectively, the “Parent Parties”), and Semnur Pharmaceuticals, Inc., a Delaware corporation (the “Company”).

WHEREAS, the Parent Parties and the Company have entered into an Agreement and Plan of Merger, dated as of August 30, 2024 (the “Merger Agreement”), providing for, among other things, the merger of Merger Sub with and into the Company, with the Company continuing as the Surv